The Weber Effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): Analysis of Sixty-Two Drugs Approved from 2006 to 2010

Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System

(2013) R Harpaz et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Adverse Event Reporting Patterns of Newly Approved Drugs in the USA in 2006: An Analysis of FDA Adverse Event Reporting System Data

(2013) Pankdeep Chhabra et al.   DRUG SAFETY

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database

(2013) Elisabetta Poluzzi et al.   DRUG SAFETY

Data Mining for Signal Detection of Adverse Event Safety Data

(2013) Hung-Chia Chen et al.   Journal of Biopharmaceutical Statistics

The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs

(2013) Rena M. Conti et al.   MEDICAL CARE

The Lalli and Weber effects and the incidence of acute non-renal adverse reactions to contrast media

(2012) H. S. Thomsen et al.   ACTA RADIOLOGICA

Drug target prediction using adverse event report systems: a pharmacogenomic approach

(2012) M. Takarabe et al.   BIOINFORMATICS

Regulatory Innovation in Postmarketing Risk Assessment and Management

(2012) J A Staffa et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Impact of Safety-Related Regulatory Action on Clinical Practice

(2012) Sigrid Piening et al.   DRUG SAFETY

Aspirin- and Clopidogrel-associated Bleeding Complications: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS

(2012) Takao Tamura et al.   International Journal of Medical Sciences

Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors

(2012) Stacie B. Dusetzina et al.   MEDICAL CARE

A Survey of the FDA's AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class

(2012) Keith B. Hoffman et al.   PLoS One

Effect of Abrupt Substitution of Gadobenate Dimeglumine for Gadopentetate Dimeglumine on Rate of Allergic-like Reactions

(2012) Matthew S. Davenport et al.   RADIOLOGY

The FDA Drug Safety Surveillance Program: Adverse Event Reporting Trends

(2011) Sheila Weiss-Smith   ARCHIVES OF INTERNAL MEDICINE

Suicidal Behavior and Depression in Smoking Cessation Treatments

(2011) Thomas J. Moore et al.   PLoS One

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System

(2011) Toshiyuki Sakaeda et al.   PLoS One

Mining multi-item drug adverse effect associations in spontaneous reporting systems

(2010) Rave Harpaz et al.   BMC BIOINFORMATICS

An Experimental Investigation of Masking in the US FDA Adverse Event Reporting System Database

(2010) Hsin-wei Wang et al.   DRUG SAFETY

Prospective Data Mining of Six Products in the US FDA Adverse Event Reporting System

(2010) Steven Bailey et al.   DRUG SAFETY

Prescription Drugs Associated with Reports of Violence Towards Others

(2010) Thomas J. Moore et al.   PLoS One

Time-to-Signal Comparison for Drug Safety Data-Mining Algorithms vs. Traditional Signaling Criteria

(2009) AM Hochberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Finding, evaluating, and managing drug-related risks: approaches taken by the US Food and Drug Administration (FDA)

(2009) Joyce Weaver et al.   Dermatologic Therapy

Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine

(2009) Barbara A. Slade   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Drugs Associated with More Suicidal Ideations Are also Associated with More Suicide Attempts

(2009) Henry T. Robertson et al.   PLoS One

Breaking the News or Fueling the Epidemic? Temporal Association between News Media Report Volume and Opioid-Related Mortality

(2009) Nabarun Dasgupta et al.   PLoS One

Antidepressants and Suicide Risk: How Did Specific Information in FDA Safety Warnings Affect Treatment Patterns?

(2009) Susan Busch et al.   PSYCHIATRIC SERVICES

Adverse Event Detection in Drug Development: Recommendations and Obligations Beyond Phase 3

(2008) Jesse A. Berlin et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect

(2008) Mara A. McAdams et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY